In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a …
J.P.
In a research report sent to investors today, J.P.
In a research report sent to investors today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised his …
Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $390, which represents a slight …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $422, following the company’s results, …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target …
In a research report issued Tuesday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of …
